RLMD
Income statement / Annual
Last year (2024), Relmada Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Relmada Therapeutics, Inc.'s net income was -$79.98 M.
See Relmada Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$1.26 K
|
$3.75 K
|
$0.00
|
$4.87 K
|
$2.63 K
|
$85.27 K
|
$54.82 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$1.26 K
|
-$3.75 K
|
$0.00
|
-$4.87 K
|
-$2.63 K
|
-$85.27 K
|
-$54.82 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.93 M
|
$54.81 M
|
$113.32 M
|
$90.62 M
|
$35.97 M
|
$7.86 M
|
$7.03 M
|
$2.94 M
|
$1.29 M
|
$6.21 M
|
| General & Administrative Expenses |
$37.72 M
|
$48.90 M
|
$47.93 M
|
$35.08 M
|
$24.87 M
|
$7.25 M
|
$5.70 M
|
$3.98 M
|
$5.93 M
|
$10.01 M
|
| Selling & Marketing Expenses |
$13.46 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$211.00 K
|
-$130.00 K
|
| Selling, General & Administrative Expenses |
$37.72 M
|
$48.90 M
|
$47.93 M
|
$35.08 M
|
$24.87 M
|
$7.25 M
|
$5.70 M
|
$3.98 M
|
$5.93 M
|
$9.88 M
|
| Other Expenses |
$0.00
|
-$293.00
|
$923.00
|
-$492.00
|
$0.00
|
$0.00
|
$0.00
|
$2.35 K
|
$0.00
|
$130.27 K
|
| Operating Expenses |
$30.18 M
|
$103.70 M
|
$161.25 M
|
$125.70 M
|
$60.84 M
|
$15.11 M
|
$12.73 M
|
$6.92 M
|
$7.22 M
|
$16.22 M
|
| Cost And Expenses |
$83.89 M
|
$103.70 M
|
$161.25 M
|
$125.70 M
|
$60.84 M
|
$15.11 M
|
$12.73 M
|
$6.92 M
|
$7.22 M
|
$16.22 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.66 M
|
$1.20 M
|
$1.40 M
|
$104.11
|
-$761.00 K
|
$0.00
|
$0.00
|
$1.75 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.34 M
|
$550.00
|
$0.00
|
| Depreciation & Amortization |
$83.89 M
|
$103.70 M
|
$2.00 K
|
$1.26 K
|
$3.75 K
|
$4.36 K
|
$4.87 K
|
$2.63 K
|
$85.27 K
|
$54.82 K
|
| EBITDA |
-$79.98 M |
$4.91 M |
-$157.04 M |
-$125.75 M |
-$59.45 M |
-$15.11 M |
-$16.55 M |
-$6.92 M |
-$6.92 M |
-$16.03 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.91 M
|
$4.91 M
|
$4.21 M
|
-$48.32 K
|
$1.38 M
|
$104.11 K
|
-$5.70 M
|
-$2.04 M
|
$932.31 K
|
$13.24 M
|
| Income Before Tax |
-$79.98 M
|
-$98.79 M
|
-$157.04 M
|
-$125.75 M
|
-$59.46 M
|
-$15.01 M
|
-$17.32 M
|
-$8.96 M
|
-$6.29 M
|
-$2.98 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$2.66 M
|
$48.32 K
|
-$1.38 M
|
$0.00
|
$4.59 M
|
$2.05 M
|
-$716.00 K
|
-$13.11 M
|
| Net Income |
-$79.98 M
|
-$98.79 M
|
-$157.04 M
|
-$125.75 M
|
-$59.46 M
|
-$15.01 M
|
-$17.32 M
|
-$8.96 M
|
-$6.29 M
|
-$2.98 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.65 |
-3.28 |
-5.3 |
-7.16 |
-3.81 |
-1.63 |
-2.74 |
-2.86 |
-2.08 |
-1.03 |
| EPS Diluted |
-2.65 |
-3.28 |
-5.3 |
-7.16 |
-3.81 |
-1.63 |
-2.74 |
-2.86 |
-2.08 |
-1.03 |
| Weighted Average Shares Out |
$30.16 M
|
$30.10 M
|
$29.63 M
|
$17.55 M
|
$15.59 M
|
$9.23 M
|
$6.31 M
|
$3.14 M
|
$3.02 M
|
$2.90 M
|
| Weighted Average Shares Out Diluted |
$30.16 M
|
$30.10 M
|
$29.63 M
|
$17.55 M
|
$15.59 M
|
$9.23 M
|
$6.31 M
|
$3.14 M
|
$3.02 M
|
$2.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
